

Company Overview — April 2021

Relay Medical Corp. CSE: RELA, OTCQB: RYMDF, Frankfurt: EIY2 - is a technology innovator headquartered in Toronto, Ontario with a team of experts focused on the development of novel technologies in the diagnostics and AI data science and IoT security sectors. Relay's product lines include of Pharmatrac, an AI healthcare technology, providing insight into medication behavior, Fionet, a data-and-device platform that enables controlled testing and tracking for pandemic response and Cybeats, a security software for the Internet of Things (IoT) and connected devices.

Company Statistics

Ticker: (OTCQB) – RYMDF Price (04/27/2021): \$0.31 52 Week Range: \$ 0.13 - 0.7272 Shares Outstanding: 239,708,804 Market Cap: \$72,871,476

Source: OTCMarkets.com, Yahoo Finance & SEC.gov

Recent News

April 14th, 2021 - <u>Relay Medical and</u> Fio Partner with LifeLabs, Canadian Healthcare Leader, to Deploy Fionet Platform for COVID-19 Testing Nationwide

March 11th, 2021 - <u>Relay Medical &</u> <u>Fio Execute Agreement to Provide</u> <u>COVID-19 Rapid Testing at Toronto</u> <u>Pearson International Airport</u>

March 10th, 2021 - <u>CEO's of</u> iRhythm, Reliq Health, AdaptHealth and Relay Medical, Driving Revenue Growth with Tech Innovation and M&A

March 3rd, 2021 - <u>Relay Acquires IoT</u> <u>Cybersecurity Firm Cybeats</u> <u>Technologies Fortifying Critical</u> <u>Pandemic Device Deployments</u>

February 25th, 2021 - <u>Relay Medical</u> and Fio Corporation Announce Launch of High-Throughput COVID-19 'Mobile Testing Toolkit' Capable of Processing 100 Tests Per Hour

Relay Medical Investment Catalyst

Launched FioNet rapid diagnostics platform for testing and tracing COVID-19 in September 2020

- Technology has been proven on other pandemics for over 1 million people
- Partnered with Canada's largest lab provider, LifeLabs for nationwide testing



L)feLabs[®]

 Deployed at Canada's largest International Airport, Toronto Pearson

Fionet's World Class Engagement



Cybeats is a unique solution for the IoT security market valued at \$7.3 billion global market by 2026. Cybeats is commercially available for all connected devices, projected to reach 30 billion devices by 2025

Relay Medical's Product Lines



Proven universal pandemic

technology. Deployed at Toronto

Airport for rapid testing, with 50

million travelers in 2019. Deployed

nationwide with LifeLabs with 20

million patient visits annually.

platform commenced Q4 2020

Sales of COVID-19 enabled



Cybeats

Cybeats software solution for connected devices, IoT Award Winning technology for Global Innovation in Security and Big Data, Cloud & Analytics.

Fully acquired Q1 2021



Pharmatrac

Al healthcare technology, provides insights and actionable changes via machine vision and learning, for medication adherence a \$4 billion global market.

Commencing user studies with two pharmacy chains and a hospital clinic in Q1 2021.

Key Management

Yoav Raiter, CEO

Yoav has 20+ years of experience leading development of large-scale software teams and medical device development management.

W. Clark Kent, President

Clark is a capital markets professional with extensive experience leading corporate development and finance.

Tom Glawdel, CSO

Tom has a PhD in Mechanical and Mechatronics Engineering with experience in the development microfluidic, molecular diagnostics and medical devices.

Paul Glavina, VP, In Vitro Diagnostics

Paul has spent 25+ years with Abbott Point of Care and its precursor, i-STAT Corporation, designing, manufacturing, and marketing the world's first handheld blood gas and analyzer.

Igal Royblat, CTO

Igal has over 25 years as a leader and innovator in the technology sector starting his career as a software developer in the Israeli Electro-Optical industry. He has spent over 10 years overseeing software and hardware development as CTO at Kangaroo. Igal holds a B.Eng. in Electrical Engineering and M.Sc. in Communications and Computer Engineering from the Ben-Gurion University in Israel and is an inventor of numerous patents

Investor Relations Contact

James S. Painter III, CEO Emerging Markets Consulting, LLC Jamespainter@emergingmarketsllc.com 321-206-6682

17(B) Compensation Disclosure:

Compensation Disclosure: Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described.

EMC has been paid \$175,000 from Relay Medical Corp. for various marketing services including this Factsheet. https://emergingmarketsllc.com/disclaimer Fionet enables scalable mass community-based screening for COVID-19, processing 60 people an hour per device with results in 30 minutes.

FionetTM enables faster, scalable and affordable screening programs with real-time results tracking:



Proven use for other infectious diseases including Ebola, HIV, and Malaria

Designed for pandemic response and management

- Can be operated by minimally trained technician
- Tests for multiple diseases, updated remotely
- Can analyze any approved test from all manufacturers, allowing for supply/demand flexibility



Fionet Mobile Device

Fionet has worked with world leading organizations to manage testing and treatment for several infectious diseases with millions of patients tested in 12+ countries

Cybeats

Award-Winning Security for IoT Devices

Cybeats offers everything that IoT manufacturers, service providers and enterprise customers need in a continuous cyber protection solution for IoT devices

- The global market for IoT security is projected to garner \$7.3 billion by 2026
- Governments are starting to regulate device security requirements



Over 64 billion devices
will be connected by 2025

Cybeats is an efficient software commercially available for manufacturers and allows for real-time updates

Cybersecurity is essential for smart buildings, critical infrastructure and medical device sectors to prevent attacks without disrupting device operations

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our actual future results may be materially different from what we expect due to risks related to our ability to raise additional funds, the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, future competition, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the SEC. These forward-looking statements speak only as of the date of this communication and the Company undertakes no obligation to revise or update any forward-looking statements for any reason.